Study: NCT02772276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 4 µmol/kg
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 4 µmol/kg
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 4 µmol/kg
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 4 µmol/kg
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 4 µmol/kg
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 4 µmol/kg
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 4 µmol/kg
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 4 µmol/kg
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 130 mg
Description: 130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- single dose of 130 mg
Description: 130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
Description: 130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
Description: 130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102-- two doses of 130 mg 24 hours apart
Description: 4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuantumLeap
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuantumLeap
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiance
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiance
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (1 or 2 sensors)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (2-part sensor)
Description: Optical Renal Function Monitor (ORFM)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brilliance (2-part sensor)
Description: Optical Renal Function Monitor (ORFM)